001     172664
005     20210129214457.0
024 7 _ |a 10.1111/ene.12621
|2 doi
024 7 _ |a WOS:000351398900008
|2 WOS
024 7 _ |a altmetric:3010711
|2 altmetric
024 7 _ |a pmid:25534579
|2 pmid
037 _ _ |a FZJ-2014-06118
082 _ _ |a 610
100 1 _ |a Petrelli
|0 P:(DE-HGF)0
|b 0
|e Corresponding Author
245 _ _ |a Cognitive training in Parkinson’s disease reduces cognitive decline in the long-term.
260 _ _ |a Oxford [u.a.]
|c 2015
|b Wiley-Blackwell
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1427450932_24554
|2 PUB:(DE-HGF)
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|0 0
|2 EndNote
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a article
|2 DRIVER
520 _ _ |a Background and purposePatients with Parkinson's disease (PD) are at high risk for cognitive dysfunction. Non-pharmacological interventions have attracted increasing interest for enhancing PD patients' cognitive functions.MethodsOne-year follow-up data (T2) of a randomized controlled trial evaluating two 6-week cognitive trainings – a structured (NEUROvitalis, NV) and an unstructured (mentally fit, MF) program − compared with a waiting list control group (CG) in non-demented PD patients (Hoehn and Yahr I–III) are presented. Forty-seven PD patients were examined at T2. Effects on overall cognitive functions (Mini-Mental State Examination and DemTect) were compared between all groups with repeated measurement analyses of variance. A combined score of the percentage change value from baseline (T0) to T2 was calculated to identify patients who retained or improved their cognitive state (responders). The risk of developing mild cognitive impairment (MCI) was analyzed.ResultsSignificant time × treatment effects on overall cognitive functions were found for both training groups, each compared separately to the CG (DemTect, P < 0.05). Nine patients (56.3%) of the NV group, seven (41.2%) of the MF group and three (21.4%) of the CG were responders. Comparing NV to CG the odds ratio was 4.7 [95% confidence interval (0.8; 33.3)], and comparing MF to CG it was 2.6 [95% confidence interval (0.4; 17.4)]. MCI risk for patients without prior MCI was 40.0% in CG, 18.2% in MF and 18.2% in NV. The odds ratio was 3 comparing NV to CG, MF to CG.DiscussionThis study gives evidence that cognitive training may be effective to prevent cognitive decline and onset of MCI in PD patients.
536 _ _ |a 572 - (Dys-)function and Plasticity (POF3-572)
|0 G:(DE-HGF)POF3-572
|c POF3-572
|x 0
|f POF III
700 1 _ |a Kaesberg, S.
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Barbe, Michael
|0 P:(DE-Juel1)131613
|b 2
700 1 _ |a Timmermann, L.
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Rosen, J.
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Fink, G. R.
|0 P:(DE-Juel1)131720
|b 5
700 1 _ |a Kessler, J.
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Kalbe, E.
|0 P:(DE-HGF)0
|b 7
|e Corresponding Author
773 _ _ |a 10.1111/ene.12621
|0 PERI:(DE-600)2020241-6
|n 4
|p 640–647
|t European journal of neurology
|v 22
|y 2015
|x 1351-5101
909 C O |o oai:juser.fz-juelich.de:172664
|p VDB
910 1 _ |a Forschungszentrum Jülich GmbH
|0 I:(DE-588b)5008462-8
|k FZJ
|b 2
|6 P:(DE-Juel1)131613
910 1 _ |a Forschungszentrum Jülich GmbH
|0 I:(DE-588b)5008462-8
|k FZJ
|b 5
|6 P:(DE-Juel1)131720
913 0 _ |a DE-HGF
|b Gesundheit
|l Funktion und Dysfunktion des Nervensystems
|1 G:(DE-HGF)POF2-330
|0 G:(DE-HGF)POF2-333
|2 G:(DE-HGF)POF2-300
|v Pathophysiological Mechanisms of Neurological and Psychiatric Diseases
|x 0
913 1 _ |a DE-HGF
|b Key Technologies
|l Decoding the Human Brain
|1 G:(DE-HGF)POF3-570
|0 G:(DE-HGF)POF3-572
|2 G:(DE-HGF)POF3-500
|v (Dys-)function and Plasticity
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
914 1 _ |y 2015
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 1 _ |0 I:(DE-Juel1)INM-3-20090406
|k INM-3
|l Kognitive Neurowissenschaften
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-Juel1)INM-3-20090406
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21